COVID-19 is an emerging, rapidly evolving situation.
What people with cancer should know: https://www.cancer.gov/coronavirus
Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers
Get the latest public health information from CDC: https://www.coronavirus.gov
Get the latest research information from NIH: https://www.nih.gov/coronavirus
Prostate cancer screening is typically done by evaluation of levels of prostate-specific antigens (PSA). Unfortunately, its effectiveness in stratifying low risk patients from those with aggressive (AG) prostate cancer is poor. Localized in the Golgi, α (1,6) fucosyltranferase (FUT8), a glycotransferase responsible for catalyzing the addition of fuco
Proteogenomic analysis may offer new insight into matching cancer patients with an effective therapy for their particular cancer. A new study identifies three molecular subtypes in head and neck squamous cell carcinoma (HNSCC) that could be used to better determine appropriate treatment. The research led by Baylor College of Medicine, Johns Hopkins University and the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) is published in the journal Cancer Cell.
Activating point mutations in ErbB/Her2 receptor tyrosine kinases have an infamous role in promoting oncogenesis across several different cancers, including breast and lung. Heterodimer activation of the ErbB2/ErbB3 oncogenic unit induces cancer cell proliferation via PI3K/AKT signaling pathways. However, its role in leukemogenesis is still largely unknown. Clinical Proteomic Tumor Analysis Consortium (CPTAC) inves
In case you missed it, this final article (part 2 of 2) in the Investigator Spotlight Series, developed and written by Dr.
Data reported can guide new therapeutic avenues for pediatric patients
A comprehensive “proteogenomic” analysis of the proteins, genes, and RNA transcription involved in pediatric brain tumors has yielded a more complete understanding of these tumors, which are the leading cause of cancer-related deaths in children. The results could help physicians more accurately identify different types of tumors and methods for treating them.
Researchers at Baylor College of Medicine, the Broad Institute of MIT and Harvard and other institutions have applied powerful proteogenomics approaches to better understand the biological complexity of breast cancer.
In a recent publication in the journal Clinical Chemistry, CPTAC investigators from Fred Hutchinson Cancer Research Center described a robust technique for evaluating biomarker expression of key receptors in patients with breast cancer bone metastasis using non-decalcified bone biopsies in imm
Protein glycosylation, the enzymatic process that attaches glycans or sugar molecules to proteins, plays a crucial role in cancer development processes, such as cell-cell adhesion, cell growth, ligand-receptor binding, and tumor metastasis. Aside from phosphorylation, other protein modifications have not been investigated in large-scale proteomic studies.
Almost 18 months ago, CPTAC researchers from theIntegrative Omics Group at Pacific Northwest National Laboratory (PNNL), developed a stream-lined technique to increase the sensitivity of peptide phospho-group identification during mass spectral analysis. The solution, called the ‘
In case you missed it, this third article (part 1 of 2) in the Investigator Spotlight Series, developed and written by Dr.
Announcing our newest data release for the Clinical Proteomic Tumor Analysis Consortium (CPTAC) Lung Squamous Cell Carcinoma (LSCC) Discovery study! Because LSCC accounts for about 30% of all lung cancers and has a ~20% 5-year survival rate, it’s imperative that cancer
In a recent issue of Nature Communications, Clinical Proteomics Tumor Analysis Consortium (CPTAC) researchers from Bing Zhang’s lab at Baylor College of Medicine describe a new bioinformatics software tool developed to evaluate the quality of variant peptide identifications. Using a deep learning algorithm, the software
The Clinical Proteomic Tumor Analysis Consortium (CPTAC) is pleased to announce its Virtual Scientific Symposium 2020, September 22nd, 2020. This year’s symposium will feature talks by leaders in the field of proteogenomics and will focus on CPTAC’s tumor characterization and translational studies for pediatric brain cancer, acute myeloid leukemia,
The NCI’s Small Business Innovation Research (SBIR) Development Center has released a program solicitation (PHS 2021-1) which includes a new, Clinical Proteomic Tumor Analysis Consortium (CPTAC)-inspired grant. The announcement calls for the development of hig
This article is the second in the Investigator Spotlight Series that was the brain child of Dr. Dawn Hayward, a NCI Communications Fellow at OCCPR, highlighting our CPTAC researchers and thier work. In case you missed it the first time, here she features CPTAC scientists Dr. David Fenyö and researcher Emily Kawaler!
Online on July 24th on Cell Systems, Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers shared the results of their first-ever, crowd-sourced NCI-CPTAC DREAM Proteogenomic Challenge.
A major goal for NCI’s Cancer Proteomic Tumor Analysis Consortium (CPTAC) is to translate proteomic technologies into clinical use to improve treatment and diagnosis of cancer. Dr. Amanda Paulovich and team from the Fred Hutchinson Cancer Research Center (members of the CPTAC Consortium) have achieved an important milestone in this regard, by establishing a Clinical Laboratory Improvement Amendments (CLIA) - certified laboratory for running targeted proteomic assays based on multiple reaction monitoring (MRM) mass spectrometry (MS).
Two new studies released July 9th, 2020 in Cell unravel the biology of lung adenocarcinoma (LUAD) using a suite of molecular techniques that, combined, provide a more complete picture of the disease than ever before.
Join Dr. Alexey Nesvizhskii, Professor of Pathology and Computational Medicine & Bioinformatics at University of Michigan, as he speaks on our next OCCPR Webinar about his ultrafast MSFragger software. The webinar will take place on Wednesday, July 15th at 1pm - registration is free, but required.
The Investigator Spotlight Series was the brain child of Dr. Dawn Hayward, an NCI Communications Fellow at OCCPR, to highlight our CPTAC researchers and thier work. In case you missed it the first time, here she features CPTAC scientist Dr. Karin Rodland. Enjoy!